About IntelliPharmaCeutics Intl (NASDAQ:IPCI)
IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001
Debt
Debt-to-Equity RatioN/A
Current Ratio0.29
Quick Ratio0.25
Price-To-Earnings
Trailing P/E Ratio-1.61
Forward P/E Ratio-4.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.51 million
Price / Sales3.71
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book47.00
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-8,850,000.00
Net Margins-217.52%
Return on Equity-2,811.75%
Return on Assets-147.15%
Miscellaneous
Employees62
Outstanding Shares43,540,000
IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions
What is IntelliPharmaCeutics Intl's stock symbol?
IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."
How were IntelliPharmaCeutics Intl's earnings last quarter?
IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) posted its quarterly earnings data on Monday, April, 16th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.04. The business earned $0.34 million during the quarter, compared to analyst estimates of $1.23 million. IntelliPharmaCeutics Intl had a negative return on equity of 2,811.75% and a negative net margin of 217.52%. View IntelliPharmaCeutics Intl's Earnings History.
When is IntelliPharmaCeutics Intl's next earnings date?
What price target have analysts set for IPCI?
3 brokerages have issued 1 year price objectives for IntelliPharmaCeutics Intl's shares. Their predictions range from $3.00 to $8.00. On average, they expect IntelliPharmaCeutics Intl's share price to reach $4.70 in the next year. View Analyst Ratings for IntelliPharmaCeutics Intl.
What are Wall Street analysts saying about IntelliPharmaCeutics Intl stock?
Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:
- 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (6/2/2018)
- 2. Maxim Group analysts commented, "1Q18 revenues were $0.3M, down from $1.1M in 4Q17 (Nov. YE). The decline owes largely to declining generic Focalin sales, citing pricing pressures in the US generics market. IPCI recently raised $4.5M through an equity financing, which extends the runway into 3Q18. However, we believe that over time the generics business for IPCI will continue to grow and provide revenue that helps offset cash burn associated with key programs: Abuse deterrent Oxycodone and PODRAS (preventing overdose); we view both programs as the long-term drivers of the company." (4/18/2018)
Who are some of IntelliPharmaCeutics Intl's key competitors?
Some companies that are related to IntelliPharmaCeutics Intl include Cardiome Pharma (CRME), Vascular Biogenics (VBLT), Trillium Therapeutics (TRIL), Neurotrope (NTRP), Aileron Therapeutics (ALRN), Novan (NOVN), LifeVantage (LFVN), Pharmaxis Limited ADR Common Stock (PXSLY), OncoSec Medical (ONCS), Novelion Therapeutics (NVLN), IMMUTEP LTD/S (IMMP), Regulus Therapeutics (RGLS), Elite Pharmaceuticals, Inc. Common Stock (ELTP), Humanigen (HGEN) and Sunesis Pharmaceuticals (SNSS).
Who are IntelliPharmaCeutics Intl's key executives?
IntelliPharmaCeutics Intl's management team includes the folowing people:
- Dr. Isa Odidi, Co-Founder, Chairman, CEO & Co-Chief Scientific Officer (Age 60)
- Dr. Amina Odidi, Pres, COO, Co-Chief Scientist Officer & Director (Age 58)
- Mr. Andrew P. Patient B.Acc, C.A., Chief Financial Officer (Age 47)
- Dr. Patrick N. Yat, Vice-Pres of Chemistry & Analytical Services (Age 60)
- Mr. Christian Akyempon, VP of Commercial Operations
Has IntelliPharmaCeutics Intl been receiving favorable news coverage?
News articles about IPCI stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IntelliPharmaCeutics Intl earned a coverage optimism score of 0.08 on Accern's scale. They also gave news coverage about the company an impact score of 47.03 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are IntelliPharmaCeutics Intl's major shareholders?
Which institutional investors are buying IntelliPharmaCeutics Intl stock?
How do I buy shares of IntelliPharmaCeutics Intl?
Shares of IPCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IntelliPharmaCeutics Intl's stock price today?
One share of IPCI stock can currently be purchased for approximately $0.47.
How big of a company is IntelliPharmaCeutics Intl?
IntelliPharmaCeutics Intl has a market capitalization of $20.45 million and generates $5.51 million in revenue each year. The company earns $-8,850,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. IntelliPharmaCeutics Intl employs 62 workers across the globe.
How can I contact IntelliPharmaCeutics Intl?
IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]
MarketBeat Community Rating for IntelliPharmaCeutics Intl (IPCI)
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe IPCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
